Today, Cynata's CEO and MD, Dr Kilian Kelly, alongside CBO Dr Mathias Kroll and Chair Dr Geoff Brooke, provided an update to investors, following the release of the FY 2024 Annual Report.

Today, Cynata's CEO, Dr Kilian Kelly, was interviewed by Proactive, following his presentation at the 18th Biotech Bioshares Summit. Watch the recording here:

Today, Cynata's CEO, Dr Kilian Kelly, presented at the MST Access Hidden Gems in Life Sciences Webinar. Watch the recording here:

Today, Cynata's CEO, Dr Kilian Kelly, presented at the MST Access Hidden Gems in Life Sciences Webinar. Watch the recording here:

MST Financial (“MST”) materials, or any portion thereof, may not be reproduced, sold or redistributed without the prior and written consent of MST. MST Access reports, updates, video interviews and other materials produced by MST Access have generally been engaged and paid by the subject company for ongoing research coverage. Please refer to full disclosures and disclaimers in the company-specific reports.

Listen to Professor John Rasko AO discussing the results of Cynata's Phase 1 clinical trial of CYP-001 in steroid-resistant acute GvHD, on the Australian Broadcasting Corporation Health Report with Dr Norman Swan and Tegan Taylor.

https://www.abc.net.au/listen/programs/healthreport/3d-printing-heart-transplant/103904548